Prognostic and predictive value of a DNA methylation-driven transcriptional signature in hepatocellular carcinoma
Received date: 2020-05-18
Revised date: 2020-07-10
Online published: 2020-07-10
Supported by
Supported by the National S&T Major Project Nos(2018ZX10732202);Supported by the National S&T Major Project Nos(2017ZX10203205)
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. DNA methylation alterations are frequently observed in malignant tumours and play critical roles in the development of cancers, including HCC. To provide novel clinical prognosis biomarkers for HCC patients, we first performed a comprehensive analysis and identified a collection of prognosis-associated genes with DNA methylation-driven expression dysregulation in HCCs. Then, we optimally established a 10-gene prognostic risk score model using the least absolute shrinkage and selection operator (LASSO) analysis. Cox's proportional hazards regression analysis revealed that the high-risk score is significantly associated with poor prognosis after being adjusted by clinical parameters, indicating its potential prognostic value. The receiver operating characteristic curve (ROC) analysis showed that this 10-gene prognostic risk score model outperformed several other publicly available models in predicting both short- and long-term prognosis. Gene set enrichment analysis revealed that the high-risk score is relevantly associated with pathways involved in cell cycle and DNA damage repair. The above results indicate that we have constructed a 10-DNA-methylation-driven-gene prognostic risk score model, which might serve as a potential prognostic biomarker for HCC patients and guide treatment decisions for patients at high risk of tumour progression.
Key words： hepatocellular carcinoma; transcriptome; epigenome; prognostic model
Hongbo Luo, Pengbo Cao, Gangqiao Zhou . Prognostic and predictive value of a DNA methylation-driven transcriptional signature in hepatocellular carcinoma[J]. Hereditas(Beijing), 2020 , 42(8) : 775 -787 . DOI: 10.16288/j.yczz.20-139
| [1] | Villanueva A . Hepatocellular carcinoma. N Engl J Med, 2019,380(15):1450-1462. |
| [2] | Samonakis DN, Kouroumalis EA . Systemic treatment for hepatocellular carcinoma: still unmet expectations. World J Hepatol, 2017,9(2):80-90. |
| [3] | Zhang JW, Xu Q, Li GL . Epigenetics in the genesis and development of cancers. Hereditas(Beijing), 2019,41(7):567-581. |
| [3] | 张競文, 续倩, 李国亮 . 癌症发生发展中的表观遗传学研究. 遗传, 2019,41(7):567-581. |
| [4] | Sun LY, Li XY, Sun ZW . Progress of epigenetics and its therapeutic application in hepatocellular carcinoma. Hereditas(Beijing), 2015,37(6):517-527. |
| [4] | 孙凌云, 李星逾, 孙志为 . 原发性肝癌的表观遗传学及其治疗. 遗传, 2015,37(06):517-527. |
| [5] | Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, Solomon A, Rajeshkumar NV, Rubio-Viqueira B, Hidalgo M . Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol, 2009,3(5-6):425-438. |
| [6] | Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR . STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 2013,29(1):15-21. |
| [7] | Kim D, Langmead B, Salzberg SL . HISAT: a fast spliced aligner with low memory requirements. Nat Methods, 2015,12(4):357-360. |
| [8] | Love MI, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 2014,15(12):550. |
| [9] | Morris TJ, Butcher LM, Feber A, Teschendorff AE, Chakravarthy AR, Wojdacz TK, Beck S . ChAMP: 450k chip analysis methylation pipeline. Bioinformatics, 2014,30(3):428-430. |
| [10] | Ritchie ME, Phipson B, Wu D, Hu YF, Law CW, Shi W, Smyth GK . Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 2015,43(7):e47. |
| [11] | Mah WC, Thurnherr T, Chow PKH, Chung AYF, Ooi LLPJ, Toh HC, Teh BT, Saunthararajah Y, Lee CGL . Methylation profiles reveal distinct subgroup of hepatocellular carcinoma patients with poor prognosis. PLoS One, 2014,9(8):e104158. |
| [12] | Friedman J, Hastie T, Tibshirani R . Regularization paths for generalized linear models via coordinate descent. J Stat Softw, 2010,33(1):1-22. |
| [13] | Blanche P, Dartigues JF, Jacqmin-Gadda H . Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med, 2013,32(30):5381-5397. |
| [14] | Steyerberg EWS, Vergouwe Y . Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J, 2014,35(29):1925-1931. |
| [15] | Zheng YJ, Liu YL, Zhao SF, Zheng ZT, Shen CY, An L, Yuan YL . Large-scale analysis reveals a novel risk score to predict overall survival in hepatocellular carcinoma. Cancer Manag Res, 2018, ( 10):6079-6096. |
| [16] | Yang Y, Lu Q, Shao XJ, Mo BH, Nie XQ, Liu W, Chen XH, Tang Y, Deng YC, Yan J . Development of a three-gene prognostic signature for hepatitis b virus associated heaptocellular carcinoma based on integrated transcriptomic analysis. J Cancer, 2018,9(11):1989-2002. |
| [17] | Long JY, Chen PP, Lin JZ, Bai Y, Yang X, Bian J, Lin Y, Wang DX, Yang XB, Zheng YC, Sang XT, Zhao HT . DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Theranostics, 2019,9(24):7251-7267. |
| [18] | Torgovnick A, Schumacher B . DNA repair mechanisms in cancer development and therapy. Front Genet, 2015,6:157. |
| [19] | Feitelson MA . Parallel epigenetic and genetic changes in the pathogenesis of hepatitis virus-associated hepatocellular carcinoma. Cancer Lett, 2006,239(1):10-20. |
| [20] | Liu LL, Dai YD, Chen JN, Zeng TT, Li Y, Chen LL, Zhu YH, Li JC, Li Y, Ma S, Xie D, Yuan YF, Guan XY . Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition by way of Akt/GSK-3β/Snail signaling. Hepatology, 2014,59(2):531-543. |
| [21] | Zhang ZY, Zhu JF, Huang YS, Li WB, Cheng HQ . MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway. Diagn Pathol, 2018,13(1):85. |
| [22] | Cao D, Song XH, Che L, Li XL, Pilo MG, Vidili G, Porcu A, Solinas A, Cigliano A, Pes GM, Ribback S, Dombrowski F, Chen X, Li L, Calvisi DF . Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells. Liver Int, 2017,37(1):80-89. |
| [23] | Liu P, Atkinson SJ, Akbareian SE, Zhou ZG, Munsterberg A, Robinson SD, Bao YP . Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling. Sci Rep, 2017,7(1):12651. |
| [24] | Wang HX, Wu KJ, Sun Y, Li YD, Wu MY, Qiao Q, Wei YJ, Han ZG, Cai B . STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro. BMB Rep, 2012,45(11):629-634. |
| [25] | Chen JX, Rajasekaran M, Xia HP, Zhang XQ, Kong SN, Sekar K, Seshachalam VP, Deivasigamani A, Goh BKP, Ooi LL, Hong WJ, Hui KM . The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway. Gut, 2016,65(9):1522-1534. |
| [26] | Desai A, Mitchison TJ . Microtubule polymerization dynamics. Annu Rev Cell Dev Biol, 1997,13:83-117. |
| [27] | Safran M, Dalah I, Alexander J, Rosen N, Stein TI, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, Sirota-Madi A, Olender T, Golan Y, Stelzer G, Harel A, Lancet D . GeneCards Version 3: the human gene integrator. Database (Oxford), 2010, 2010: baq020. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号
